Sanofi and Regeneron's Dupixent Approved in Japan for Moderate to Severe Bullous Pemphigoid Treatment

Sanofi and Regeneron's Dupixent has been approved in Japan as the first targeted treatment for adults with moderate to severe bullous pemphigoid. The approval is based on a pivotal study showing that the number of patients treated with Dupixent who achieved durable remission of the disease by week 36 was more than four times higher than in the placebo group. Dupixent is the seventh indication approved for Dupixent in Japan.